JACC: Basic to Translational Science (Apr 2016)

Transcriptomic Analysis Identifies the Effect of Beta-Blocking Agents on a Molecular Pathway of Contraction in the Heart and Predicts Response to Therapy

  • Bettina Heidecker, MD,
  • Michelle M. Kittleson, MD, PhD,
  • Edward K. Kasper, MD,
  • Ilan S. Wittstein, MD,
  • Hunter C. Champion, MD, PhD,
  • Stuart D. Russell, MD,
  • Kenneth L. Baughman, MD,
  • Joshua M. Hare, MD

DOI
https://doi.org/10.1016/j.jacbts.2016.02.001
Journal volume & issue
Vol. 1, no. 3
pp. 107 – 121

Abstract

Read online

Over the last decades, beta-blockers have been a key component of heart failure therapy. However, currently there is no method to identify patients who will benefit from beta-blocking therapy versus those who will be unresponsive or worsen. Furthermore, there is an unmet need to better understand molecular mechanisms through which heart failure therapies, such as beta-blockers, improve cardiac function, in order to design novel targeted therapies. Solving these issues is an important step towards personalized medicine. Here, we present a comprehensive transcriptomic analysis of molecular pathways that are affected by beta-blocking agents and a transcriptomic biomarker to predict therapy response.

Keywords